Search hospitals > Connecticut > Hartford
Smilow Cancer Hospital Care Center at Saint Francis
Claim this profileHartford, Connecticut 06105
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Recurrence
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
300 reported clinical trials
42 medical researchers
Summary
Smilow Cancer Hospital Care Center at Saint Francis is a medical facility located in Hartford, Connecticut. This center is recognized for care of Cancer, Breast Cancer, Recurrence, Lung Cancer, Adenocarcinoma and other specialties. Smilow Cancer Hospital Care Center at Saint Francis is involved with conducting 300 clinical trials across 409 conditions. There are 42 research doctors associated with this hospital, such as Alessandro Santin, Amer M. Zeidan, Joseph W. Kim, MD, and Iris Isufi, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Alessandro SantinSmilow Cancer Hospital at Yale New Haven4 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
15 reported clinical trials
24 drugs studied
Amer M. ZeidanYale Cancer Center3 years of reported clinical research
Studies Leukemia
Studies Myelodysplastic Syndrome
14 reported clinical trials
23 drugs studied
Joseph W. Kim, MDYale University7 years of reported clinical research
Studies Cancer
Studies Prostate Cancer
11 reported clinical trials
23 drugs studied
Iris Isufi, MDYale Cancer Center7 years of reported clinical research
Studies Lymphoma
Studies B-Cell Lymphoma
9 reported clinical trials
18 drugs studied
Clinical Trials running at Smilow Cancer Hospital Care Center at Saint Francis
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Multiple Myeloma
Prostate Cancer
Urothelial Carcinoma
Bladder Cancer
Squamous Cell Carcinoma
Follicular Lymphoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Smilow Cancer Hospital Care Center at Saint Francis?
Smilow Cancer Hospital Care Center at Saint Francis is a medical facility located in Hartford, Connecticut. This center is recognized for care of Cancer, Breast Cancer, Recurrence, Lung Cancer, Adenocarcinoma and other specialties. Smilow Cancer Hospital Care Center at Saint Francis is involved with conducting 300 clinical trials across 409 conditions. There are 42 research doctors associated with this hospital, such as Alessandro Santin, Amer M. Zeidan, Joseph W. Kim, MD, and Iris Isufi, MD.